French biotech Abivax (Euronext: FR0012333284) has completed an initial public offering (IPO), listing on the Nasdaq global market with 20,325,500 new ordinary shares being issued.
The aggregate gross proceeds amounted to around 223 million euros ($236 million), with trading commencing on October 20.
Morgan Stanley and Leerink Partners acted as joint global coordinators for the offering, while LifeSci Capital acted as lead manager for the US offering.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze